Revised Effective Nov. 1, 2018: Clinical Coverage Policy 11A-10, Hematopoietic Stem-Cell Transplantation (HSCT) for Central Nervous System (CNS) Embryonal Tumors & Ependymoma

<p><em>Hematopoietic Stem-Cell Transplantation for Central Nervous System Embryonal Tumors &amp; Ependymoma, 11A-10</em> has been revised effective&nbsp;Nov. 1, 2018.</p>

Author: GDIT Call Center, (800) 688-6696

Hematopoietic Stem-Cell Transplantation (HSCT) for Central Nervous System (CNS) Embryonal Tumors & Ependymoma, 11A-10 has been revised. The revisions, which will become effective Nov. 1, 2018, will add coverage criteria for tandem autologous stem-cell transplants for high-risk CNS embryonal tumors.

Related Topics: